Looks like you’re on the UK site. Choose another location to see content specific to your location
Waters launches new Cortecs T3 and Cortecs Shield RP18 columns
Waters has announced the launch of two new liquid chromatography columns for use in high-performance chromatographic separation processes.
The new Cortecs T3 and Cortecs Shield RP18 columns are designed to help scientists to obtain more information per analysis and reduce the cost of analysing a range of complex samples.
Its 1.6 micron particle columns work alongside the company's Acquity UPLC instrument platform to deliver an approximately 40 percent greater increase in separations efficiency, when compared to fully porous particles of an equivalent particle size.
Meanwhile, the highly-efficient Cortecs 2.7 micron particle columns are designed for use with the Acquity Arc UHPLC system and the Waters Alliance HPLC system, operating at lower backpressures to allow for the use of longer column lengths to improve resolution or shorten analysis times.
These columns are ideal for the analysis of samples such as biomarkers, natural products, counterfeit cosmetics, synthetic cannabinoids, veterinary drugs, drinking water and vitamins.
Doug McCabe, director of consumable product management at Waters, said: "Today's scientists want more tools for improving the resolution, speed, selectivity and sensitivity of their UPLC, UHPLC and HPLC separations. Cortecs Columns deliver the batch-to-batch reproducibility, robustness, and quality that customers have come to expect."
With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard